UNSPSC 51172475: Loperamide/simethicone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.

UNSPSC 51172475 Loperamide/simethicone, a Commodity code, covers individual pharmaceutical products that state and local governments procure primarily through two channels: direct government purchasing and cooperative purchasing vehicles. The recent solicitations show that loperamide/simethicone falls within broader pharmaceutical procurement frameworks where state agencies, counties, and cooperative alliances source branded and generic pharmaceuticals, over-the-counter products, and ancillary medicines to support corrections departments, health benefit programs, and public health facilities. Issuing bodies include state health and human services commissions, county corrections and community supervision departments, and multistate cooperative purchasing organizations serving state and local members. The scope encompasses supply of products meeting FDA cGMP and Drug Supply Chain Security Act compliance, with manufacturers required to maintain relationships with authorized wholesalers, provide detailed product coding (NDC, SKU, UPC), and meet specific shelf-life and expiration requirements.

Geographic activity centers on Texas and the Upper Midwest, with recent procurement spanning the Texas Department of Criminal Justice, Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving state and local facilities across Minnesota and Oregon. Representative recent opportunities include the Minnesota Department of Administration's MMCAP RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with proposals due March 26, 2026, establishing multiple contracts effective July 1, 2026, and the Texas Health and Human Services Commission RFI (HHS0017013) posted April 3, 2026 to solicit vendor capabilities for direct-to-manufacturer prescription programs. While these solicitations address pharmaceutical procurement broadly rather than loperamide/simethicone specifically, they establish the contracting mechanisms and vendor requirements state and local buyers apply when sourcing individual pharmaceutical commodities under this code.